Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Magle Chemoswed Holding AB (publ) (MAGLE.ST)
Malmö, SE
Magle Chemoswed Holding AB (publ), based in Malmö, Sweden, specializes in the research, development, and manufacturing of products within the pharmaceutical chemistry and technology sectors. The company's core activities include the process development and production of Active Pharmaceutical Ingredients (APIs), as well as the innovation and manufacturing of advanced wound care and diagnostic products, primarily leveraging its proprietary degradable starch microsphere technology. Its API portfolio features Warfarin sodium, used as an anticoagulant; Melperone hydrochloride, an antipsychotic agent; Isradipine, a calcium channel blocker for hypertension; Amantadine sulfate, for central nervous system disorders; and Benserazide hydrochloride, utilized with L-Dopa in Parkinson's disease treatment. Furthermore, Magle Chemoswed offers a range of medical devices for advanced wound care, surgical diagnostics, and drug delivery. These include EmboCept S, a microsphere-based device for vascular occlusion in liver and lung tumors; SmartGel, an innovative non-allergenic hydrogel derived from their microsphere platform; SmartPAN, a diagnostic tool for detecting pancreatic fluid leakage during surgical procedures; and EmboCept M, designed for managing benign prostatic hyperplasia. The company provides contract services to the pharmaceutical and medical device industries. Founded in 1944, Magle Chemoswed Holding AB (publ) operates as a subsidiary of Magle AB.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.87% | -1.14% | -18.31% | -55.95% | -81.09% | -79.65% | -87.30% | -89.08% | -90.53% | -82.68% | -82.68% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-06 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+19.9% ★ Q1'26: -15.7% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-1,434.5% Q1'26: -1,725.9% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-14.3% Q1'26: -11.3% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-44.0% Q1'26: -25.9% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-17.1% Q1'26: -10.8% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+0.7% ★ Q1'26: +0.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-14.28× Q1'26: -13.53× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
142.34M
est: 137.75M (+3.3%)
|
132.15M
est: 138.20M (-4.4%)
|
145.68M
est: 134.78M (+8.1%)
|
170.44M
est: 160.30M (+6.3%)
|
236.04M
est: 255.50M (-7.6%)
|
282.92M
est: 344.00M (-17.8%)
|
377.00M
377.00M – 377.00M
+9.6% YoY
|
406.00M
406.00M – 406.00M
+7.7% YoY
|
| EBITDA |
14.88M
est: 23.52M (-36.7%)
|
18.14M
est: 23.60M (-23.1%)
|
25.77M
est: 23.02M (+12.0%)
|
31.40M
est: 27.37M (+14.7%)
|
59.21M
est: 33.91M (+74.6%)
|
-24.25M
est: 45.65M (-153.1%)
|
50.03M
50.03M – 50.03M
+9.6% YoY
|
53.88M
53.88M – 53.88M
+7.7% YoY
|
| EBIT |
3.21M
est: 10.10M (-68.2%)
|
6.49M
est: 10.13M (-36.0%)
|
12.79M
est: 9.88M (+29.5%)
|
18.30M
est: 11.75M (+55.7%)
|
23.53M
est: -4.91M (+579.2%)
|
-124.49M
est: -6.61M (-1,783.4%)
|
-7.24M
-7.24M – -7.24M
-9.6% YoY
|
-7.80M
-7.80M – -7.80M
-7.7% YoY
|
| Net Income |
1.82M
est: 2.86M (-36.4%)
|
4.28M
est: 11.04M (-61.2%)
|
9.15M
est: 14.31M (-36.1%)
|
12.17M
est: 8.17M (+48.9%)
|
11.94M
est: 24.68M (-51.6%)
|
-159.89M
est: 6.19M (-2,681.0%)
|
28.91M
28.91M – 28.91M
+366.7% YoY
|
49.56M
49.56M – 49.56M
+71.4% YoY
|
| SGA |
40.80M
est: 58.95M (-30.8%)
|
43.44M
est: 59.14M (-26.5%)
|
-1.80M
est: 57.68M (-103.1%)
|
134.13M
est: 68.60M (+95.5%)
|
176.92M
est: 94.69M (+86.9%)
|
—
est: 127.48M (-100.0%)
|
139.71M
139.71M – 139.71M
+9.6% YoY
|
150.46M
150.46M – 150.46M
+7.7% YoY
|
| EPS |
0.24
est: 0.14 (+72.1%)
|
0.43
est: 0.54 (-20.1%)
|
0.85
est: 0.70 (+21.9%)
|
1.13
est: 0.40 (+183.6%)
|
0.93
est: 1.20 (-22.2%)
|
-7.74
est: 0.30 (-2,680.0%)
|
1.40
1.40 – 1.40
+366.7% YoY
|
2.40
2.40 – 2.40
+71.4% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-06-03 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-06-02 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-06-01 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-25 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hans Henrik Lidgard | Founder & Director | 248.0K | male |
| Barbara Willkomm | Chief Human Resources Officer | — | — |
| Fredrik Andersson | Chief Operations Officer | — | male |
| Aaron Wong | CFO & Interim CEO | — | male |
| Helena Ossmer Thedius | Chief Marketing & Innovation Officer | — | female |
| Megi Medzmariashvili | General Counsel | — | female |
| Simon Jegou | Chief Strategy Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MAGLE.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
